Larimar Therapeutics Inc.
Clinical‑stage biotech Larimar Therapeutics leverages a cell‑penetrating peptide platform to develop rare‑disease therapies; its Phase‑2 lead, CTI‑1601, targets Friedreich’s ataxia.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 65
- HQ: Bala Cynwyd
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.